Login | Register

Trastuzumab Emtansine (T-DM1) Significantly Improves Breast Cancer Survival

The investigational drug, Trastuzumab Emtansine (T-DM1), improves survival of patients with HER2-Positive metastatic breast cancer "significantly", Genentech Inc. announced today as it published highlights of its Phase III EMILIA study results. T-DM1 was compared to lapatinib and Xeloda (capecitabine) combination therapy...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *